Biogen

YTD

ALL

Trade Biogen 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BIIB

Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis.

CEO

Christopher A. Viehbacher

CEOChristopher A. Viehbacher

Employees

7,605

Employees7,605

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

1978

Founded1978

Employees

7,605

Employees7,605

BIIB Key Statistics

Market cap

19.67B

Market cap19.67B

Price-Earnings ratio

13.25

Price-Earnings ratio13.25

Dividend yield

—

Dividend yield—

Average volume

1.24M

Average volume1.24M

High today

$134.59

High today$134.59

Low today

$132.37

Low today$132.37

Open price

$133.05

Open price$133.05

Volume

1.04M

Volume1.04M

52 Week high

$238.00

52 Week high$238.00

52 Week low

$110.04

52 Week low$110.04

BIIB News

TipRanks 3d

Biogen’s Phase 3 Study on Felzartamab for IgA Nephropathy: A Market Game-Changer?

Biogen Inc. ((BIIB)), Biogen ((CC:HTER)) announced an update on their ongoing clinical study. Don’t Miss TipRanks’ Half-Year Sale Take advantage of TipRanks P...

TipRanks 3d

Biogen, Stoke Therapeutics present data from studies of zorevunersen

Biogen (BIIB) and Stoke Therapeutics (STOK) announced the presentation of data from an analysis that informed the design of the Phase 3 EMPEROR study and evalua...

Simply Wall St 4d

Biogen Insiders Sold US$1.8m Of Shares Suggesting Hesitancy

In the last year, many Biogen Inc. ( ) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whether insiders...

Analyst ratings

49%

of 37 ratings

Buy

48.6%

Hold

48.6%

Sell

2.7%

People also own

Based on the portfolios of people who own BIIB. This list is generated using Robinhood data, and it’s not a recommendation.